Plasma cell leukemia: update on biology and therapy. Mina R et al. Leuk Lymphoma. 2016 Nov 6:1-10. [Epub ahead of print]. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. Maciocia N et al. Hematol Oncol. 2016 Nov 2. doi: 10.1002/hon.2345. [Epub ahead of print]. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition…
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma(MUK-six): a multicentre, open-label, phase 1/2 trial. Popat R et al. Lancet Haematol. 2016 Nov 11. pii: S2352-3026(16)30165-X. doi: 10.1016/S2352-3026(16)30165-X. [Epub ahead of print]. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Sanchez L et al. Br J Haematol. 2016…
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Li N et al. Nat Commun. 2016 Nov 24;7:13656. doi: 10.1038/ncomms13656. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. Jiménez C et al. J Mol Diagn. 2016 Nov 15. pii: S1525-1578(16)30186-6. doi: 10.1016/j.jmoldx.2016.08.004. [Epub ahead of print]. Exome copy number variation detection:…
Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. Malard F et al. Cancer Treat Rev. 2016 Nov 15;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. [Epub ahead of print]. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Musto P et al. Ann Oncol. 2016 Nov 17. pii: mdw606. [Epub ahead of print]. Aging, ‘Treating the Older Patient’. Rosko A et al. Biol…
Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study. Isoda A et al. Int J Hematol. 2016 Nov 21. [Epub ahead of print]. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients. Kurtz JE et al. Onco Targets Ther. 2016 Oct 28;9:6689-6693. eCollection 2016. Percutaneous sacroplasty…
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractorymultiple myeloma patients. Kotchetkov R et al. Cancer Med. 2016 Nov 18. doi: 10.1002/cam4.799. [Epub ahead of print]. Safety of proteasome inhibitors for treatment of multiple myeloma. Schlafer D et al. Expert Opin Drug Saf. 2016 Nov 14. [Epub ahead of print]. Ixazomib Cardiotoxicity: A Possible Class Effect of Proteasome Inhibitors. Jouni H et al. Am J…
Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Spoerl S et al. Transfusion. 2016 Nov 18. doi: 10.1111/trf.13883. [Epub ahead of print]. Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Cornell RF et al. Biol Blood Marrow Transplant. 2016 Nov 15. pii: S1083-8791(16)30489-X. doi: 10.1016/j.bbmt.2016.11.011. [Epub ahead of print]. Absence…
A study, funded by Myeloma UK, has discovered a mechanism that may explain how a genetic variant increases the risk of developing myeloma. Published in the latest issue of Nature Communications, researchers at The Institute of Cancer Research, London investigated the functional effects of the most highly associated variant they had identified from a previously conducted…
The Myeloma UK Clinical Trial Network (CTN) has achieved another significant milestone with data from the MUK six trial published in the latest issue of Lancet Haematology. MUK six, a Phase I/II multicentre open label trial aimed to determine the safety and both the optimum and maximum dose of panobinostat when used in combination with once-weekly Velcade,…
